Why Super Micro Computer (SMCI) Is Down 6.4% After DOJ Export-Control Indictment Tied To Nvidia Servers

• The U.S. Justice Department has unsealed an indictment against three individuals linked to Super Micro Computer for allegedly diverting advanced Nvidia-powered servers worth about US$2.50 billions to Chinese customers in breach of U.S. export controls, triggering multiple shareholder class actions accusing the company of misleading disclosures on sales and compliance.
• Although Super Micro itself has not been named as a defendant, the involvement of a co-founder, governance upheaval, and alleged control weaknesses raise material questions about its compliance culture and long-term access to critical GPU supply.
• We’ll now examine how these export-control allegations against executives could affect Super Micro’s previously optimistic AI server growth narrative and risks.

Invest in the nuclear renaissance through our list of 94 elite nuclear energy infrastructure plays powering the global AI revolution.

Super Micro Computer Investment Narrative Recap

To own Super Micro today, you need to believe that its AI server positioning and deep Nvidia integration can offset legal and governance overhangs. The export-control indictment against individuals tied to the company cuts close to the core short term catalyst: continued access to high end GPUs and large AI data center orders. At the same time, the biggest near term risk has clearly shifted toward compliance credibility and potential strain in key supplier and customer relationships.

The most relevant recent announcement is Super Micro’s March 20 appointment of DeAnna Luna as acting Chief Compliance Officer, alongside co founder Wally Liaw’s board resignation. For investors, this move sits directly at the intersection of the DOJ allegations and the company’s growth story in AI servers, because it highlights both the seriousness of the compliance issues and the early steps management is taking to strengthen export control oversight while AI demand remains a central driver.

But behind the AI growth story, the export control investigations and class actions introduce an additional layer of risk that investors should understand in detail before they...

Read the full narrative on Super Micro Computer (it's free!)

Super Micro Computer's narrative projects $48.2 billion revenue and $2.4 billion earnings by 2028. This requires 29.9% yearly revenue growth and a $1.4 billion earnings increase from $1.0 billion today.

Uncover how Super Micro Computer's forecasts yield a $48.53 fair value, a 116% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue could reach about US$56.9 billion and earnings US$2.0 billion by 2029, yet still seeing excess inventory and commoditization as major threats, and the latest export control issues may push that more pessimistic view even further, which is why you should compare these assumptions with your own expectations.

Explore 19 other fair value estimates on Super Micro Computer - why the stock might be worth just $34.53!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Super Micro Computer research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Super Micro Computer research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Super Micro Computer's overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
• Find 58 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com